Tag: surface plasmon resonance market size

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Tumor Marker Testing Market Growth Potential: How Will Market Size Change Through 2030?

The market for tumor marker testing has experienced robust expansion recently, projecting a rise from $18.6 billion in 2025 to $20.12 billion in 2026, fueled by a compound annual growth rate (CAGR) of 8.2%. This historical growth trajectory is attributable to a confluence of factors including escalating cancer prevalence, heightened adoption of oncological laboratory diagnostics, the proliferation of cancer testing services within hospitals, the existence of well-recognized biochemical markers, and the expansion of diagnostic laboratory networks.

The global market for tumor marker testing is poised for significant expansion, projecting a valuation of $27.23 billion by 2030, exhibiting a compound annual growth rate of 7.9%. This anticipated upward trajectory is primarily fueled by an escalating need for the early identification of cancer, a broader embrace of precision oncology methodologies, the proliferation of companion diagnostics, the increasing utility of biomarkers in guiding therapeutic choices, and ongoing breakthroughs in cancer biomarker research. Key developments expected to shape this market during the forecast period encompass a greater utilization of combined tumor marker testing panels, a rise in the adoption of blood-based diagnostic tools for cancer, a more profound integration of tumor markers into the process of monitoring treatment efficacy, the widening scope of early cancer detection initiatives, and a heightened emphasis on individualized cancer care strategies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20668&type=smp

Tumor Marker Testing Market Demand Drivers: What Is Fueling Industry Growth?

The escalating incidence of cancer is anticipated to be a significant catalyst for the expansion of the tumor marker testing sector. Cancer, defined by the aberrant proliferation of cells that can infiltrate adjacent tissues and metastasize throughout the body via circulatory and lymphatic pathways, is becoming more widespread. Contributing to this upward trend in cancer diagnoses are demographic shifts like an aging populace, heightened exposure to environmental factors, evolving lifestyles, and advancements in diagnostic capabilities. Tumor marker tests play a crucial role in the management of numerous cancers, aiding in their identification, assessing therapeutic efficacy, and identifying recurrence by quantifying distinct biological substances indicative of malignancy. Supporting this, the National Health Service, a UK governmental body, reported that in 2023, 354,820 new cancer cases were identified, averaging 972 daily, an increase of 8,605 cases compared to the previous year. Consequently, the rising burden of cancer directly fuels the growth of the market for tumor marker diagnostics.

Tumor Marker Testing Market Segment Performance And Strategic Opportunities

The tumor marker testing market covered in this report is segmented –

1) By Product: Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines

2) By Methods: Screening, Imaging, Theranostics, Other Methods

3) By Application: Hospitals, Commercial Or Private Laboratories, Physician Offices Or Group Practices, Cancer Clinics, Ambulatory Care Centers

Subsegments:

1) By Biochemical Markers: Alpha-fetoprotein (AFP), Prostate-Specific Antigen (PSA), Carcinoembryonic Antigen (CEA), Cancer Antigen 125 (CA 125), Cancer Antigen 19-9 (CA 19-9), Human Chorionic Gonadotropin (hCG)

2) By Oncogenes: HER2 Or neu, KRAS, BRAF, EGFR (Epidermal Growth Factor Receptor), c-MYC, p53

3) By Growth Factors: Vascular Endothelial Growth Factor (VEGF), Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor-beta (TGF-β), Fibroblast Growth Factor (FGF), Insulin-like Growth Factor (IGF)

4) By Hormones: Estrogen Receptors (ER), Progesterone Receptors (PR), Thyroglobulin, Calcitonin, Adrenocorticotropic Hormone (ACTH), Gastrin

5) By Colony Stimulating Factors: Granulocyte Colony-Stimulating Factor (G-CSF), Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Macrophage Colony-Stimulating Factor (M-CSF)

6) By Lymphokines: Interleukin-2 (IL-2), Interferon-gamma (IFN-γ), Tumor Necrosis Factor-alpha (TNF-α), Interleukin-6 (IL-6)

Tumor Marker Testing Market Innovation Trends: Which Developments Are Transforming The Industry?

Companies dominant in the tumor marker testing sector are directing greater attention toward the creation of sophisticated tests, specifically molecular testing options, as a means to secure a more advantageous position within the marketplace. Molecular testing solutions encompass cutting-edge diagnostic approaches that scrutinize genetic material, including DNA and RNA, for the identification of alterations, infectious agents, or particular biomarkers at a fundamental molecular level. As an illustration, during April 2024, RGCC International GmbH, a Swiss entity engaged in personalized cancer therapies, introduced Onco-D-clare, a pioneering test designed for cancer detection. This novel test empowers individuals to identify cancer manifestation prior to the onset of visible symptoms, by ingeniously integrating principles of molecular biology with artificial neural networks. The operational mechanism of Onco-D-clare involves separating peripheral blood mononuclear cells from collected blood specimens, followed by an in-depth examination of gene expression patterns across a spectrum exceeding ninety genes.

Tumor Marker Testing Market Key Players: Which Companies Shape Industry Competition?

Major companies operating in the tumor marker testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche AG, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson and Company (BD), Quest Diagnostics Inc., Agilent Technologies Inc, Hologic Inc., Illumina Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Qiagen N.V., DiaSorin S.p.A., Myriad Genetics, Ortho Clinical Diagnostics PLC, Veracyte Inc., Biodesix Inc., Biocept Inc., Proteomedix AG, OncoCyte Corporation, Biocartis NV

Access The Complete Tumor Marker Testing Market Report:

https://www.thebusinessresearchcompany.com/report/tumor-marker-testing-global-market-report

Tumor Marker Testing Market Regional Analysis: Which Region Leads By Revenue?

North Americawas the largest region in the tumor marker testing market in 2025. The regions covered in the tumor marker testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Surface Plasmon Resonance Market Growth Potential: How Will Market Size Change Through 2030?

Fueled by burgeoning pharmaceutical and biotechnology research endeavors, coupled with the escalating utilization of biomolecular interaction analysis and expanded academic life science investigations, the surface plasmon resonance market is poised for substantial expansion. The market is projected to climb from $1.33 billion in 2025 to $1.49 billion by 2026, demonstrating a compound annual growth rate of 11.8%. This upward trajectory is underpinned by the increasing need for analytical precision instruments and the continuous advancement of sophisticated optical sensing technologies, which have collectively driven recent market acceleration.

The surface plasmon resonance market is poised for substantial expansion in the upcoming years, projected to reach $2.3 billion by 2030, fueled by a compound annual growth rate of 11.5%. This anticipated surge is underpinned by several key drivers, including escalating investments in the development of biologics and biosimilars, a growing need for high-throughput screening technologies, the advancement of personalized medicine research, the increasing integration of biosensors in diagnostic applications, and a heightened emphasis on real-time molecular analytics. Furthermore, significant trends shaping the market landscape during this forecast period encompass the broader adoption of high-sensitivity surface plasmon resonance imaging systems, a greater demand for label-free biomolecular analysis methodologies, the expanding incorporation of surface plasmon resonance within drug discovery processes, the development of more portable and multi-channel surface plasmon resonance sensors, and an intensified concentration on the analysis of real-time molecular interactions.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20655&type=smp

Surface Plasmon Resonance Market Growth Drivers: What Factors Are Accelerating Expansion?

The expansion of the surface plasmon resonance market is anticipated to benefit from the growing trend towards personalized medicine. This approach to healthcare involves customizing treatment and prevention plans by considering a person’s unique genetic makeup, environmental influences, and lifestyle choices. Factors such as progress in genomics, the emergence of targeted therapies, and the desire for more accurate and successful medical interventions are fueling the adoption of personalized medicine. Surface plasmon resonance plays a crucial role in this field by facilitating immediate examination of biomolecular interactions, aiding in the detection of specific biomarkers, and refining drug treatments suited for individual patients. Illustrating this, in February 2024, the Personalized Medicine Coalition reported that in 2023, the FDA greenlit 16 novel personalized treatments for individuals with rare diseases, a notable increase from the 6 approvals in 2022, with the 2023 approvals also encompassing seven cancer medications and three for various other ailments. Consequently, the heightened utilization of personalized medicine is a significant catalyst for the surface plasmon resonance market’s advancement.

Surface Plasmon Resonance Market Segments: Where Are The Largest Growth Opportunities?

The surface plasmon resonance market covered in this report is segmented –

1) By Product Type: Imaging System, Sensor System, Reagents

2) By Technology: Prism-Based Surface Plasmon Resonance (SPR), Grating-Based Surface Plasmon Resonance (SPR), Other Technologies

3) By Application: Drug Discovery, Drug Formulation, Controlled Drug Release, Drug Cell Interaction, Material Science, Biosensors

4) By End-User: Academic And Research Institutes, Food And Beverage Industry, Biopharmaceutical Companies, Contract Research Organizations (CROs), Other End-Users

Subsegments:

1) By Imaging System: 2D Imaging Systems, 3D Imaging Systems, High-Resolution Imaging Systems

2) By Sensor System: Optical Sensor Systems, Portable Sensor Systems, Multi-channel Sensor Systems

3) By Reagents: Binding Reagents, Sample Preparation Reagents, Stabilizing Reagents

Surface Plasmon Resonance Market Trends: What Is Shaping Future Industry Growth?

Leading enterprises within the surface plasmon resonance sector are prioritizing the creation of sophisticated biomolecular analysis solutions, exemplified by advanced SPR biosensor systems designed for high throughput, aiming to enhance their market standing. The SPR technique leverages an optical effect occurring at the boundary between a metal and a dielectric material for the immediate, label-free detection of molecular interactions. A notable illustration of this trend emerged in February 2023 when Carterra, a biotechnology instrumentation firm headquartered in the United States, introduced its LSA^XT, a high-throughput SPR platform distinguished by its heightened sensitivity, substantially improved sample processing capacity, and diminished sample volume requirements, thereby facilitating the effective evaluation of membrane proteins, small molecules, and kinetic binding profiles. The integration of such highly sensitive, high-throughput SPR instruments empowers pharmaceutical and biotechnology organizations to expedite the processes of drug discovery and the characterization of biological agents. Nevertheless, this evolutionary path simultaneously intensifies the imperative for instrument manufacturers to guarantee consistent results and adeptly handle escalating data quantities.

Surface Plasmon Resonance Market Major Participants And Competitive Dynamics

Major companies operating in the surface plasmon resonance market are GE HealthCare Technologies Inc., Sartorius AG, Cytiva, Bio-Rad Laboratories Inc., Bruker Corporation, HORIBA Ltd., Quanterix Corporation, Jubilant Biosys Limited, Quantum Design Inc., Reichert Inc., NanoSPR Devices, Creative BioMart Inc., Biocompare, Carterra Inc., NICOYA AB, Biosensing Instrument Inc., Plexera LLC, Insplorion AB, BioNavis Ltd., Affinité Instruments, IBIS Technologies B.V.

Access The Complete Surface Plasmon Resonance Market Report:

https://www.thebusinessresearchcompany.com/report/surface-plasmon-resonance-global-market-report

Surface Plasmon Resonance Market Regional Outlook: Where Are The Largest Opportunities Located?

North Americawas the largest region in the surface plasmon resonance market in 2025. The regions covered in the surface plasmon resonance market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Growth In Market Value Is Anticipated For The Surface Plasmon Resonance Market Between 2026 And 2030?

The surface plasmon resonance market has witnessed rapid growth in recent years. It is forecast to grow from $1.33 billion in 2025 to $1.49 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.8%. The historical expansion of this market can be attributed to the proliferation of pharmaceutical and biotech research activities, the wider adoption of biomolecular interaction studies, growth in academic life science research, increasing demand for analytical precision tools, and the availability of advanced optical sensing technologies.

The surface plasmon resonance market is anticipated to experience swift expansion over the coming years. It is forecast to reach $2.3 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.5%. This growth in the forecast period is attributed to several factors, including increasing investment in biologics and biosimilars development, a rising demand for high-throughput screening tools, the expansion of personalized medicine research, growing adoption of biosensors in diagnostics, and an increasing focus on real-time molecular analytics. Key trends during this period are expected to encompass the increasing adoption of high-sensitivity SPR imaging systems, a rising demand for label-free biomolecular analysis, the growing integration of SPR in drug discovery pipelines, the expansion of portable and multi-channel SPR sensors, and an enhanced focus on real-time interaction analysis.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20655&type=smp

What Major Growth Factors Are Impacting The Surface Plasmon Resonance Market?

The expanding integration of personalized medicine is projected to stimulate the growth of the surface plasmon resonance market moving forward. Personalized medicine defines a customized healthcare methodology that utilizes a person’s genetic, environmental, and lifestyle elements to develop unique treatment and prevention programs. The increasing acceptance of personalized medicine is propelled by breakthroughs in genomics, the development of targeted therapies, and the need for more precise and effective therapeutic options. Surface plasmon resonance supports personalized medicine by enabling the live analysis of biomolecular interactions, assisting in the identification of particular biomarkers, and optimizing drug regimens specifically for individual patients. For example, in February 2024, data from the Personalized Medicine Coalition, a US-based hospital and health care organization, indicated that the FDA cleared 16 new personalized treatments for rare disease patients in 2023, an increase from 6 in 2022. The new personalized treatments approved in 2023 additionally comprised seven cancer drugs and three for various other conditions and diseases. Therefore, the growing adoption of personalized medicine is a key driver for the surface plasmon resonance market’s expansion.

How Are Different Segment Groups Identified Within The Surface Plasmon Resonance Market?

The surface plasmon resonance market covered in this report is segmented –

1) By Product Type: Imaging System, Sensor System, Reagents

2) By Technology: Prism-Based Surface Plasmon Resonance (SPR), Grating-Based Surface Plasmon Resonance (SPR), Other Technologies

3) By Application: Drug Discovery, Drug Formulation, Controlled Drug Release, Drug Cell Interaction, Material Science, Biosensors

4) By End-User: Academic And Research Institutes, Food And Beverage Industry, Biopharmaceutical Companies, Contract Research Organizations (CROs), Other End-Users

Subsegments:

1) By Imaging System: 2D Imaging Systems, 3D Imaging Systems, High-Resolution Imaging Systems

2) By Sensor System: Optical Sensor Systems, Portable Sensor Systems, Multi-channel Sensor Systems

3) By Reagents: Binding Reagents, Sample Preparation Reagents, Stabilizing Reagents

Which Trends Are Shaping The Surface Plasmon Resonance Market Landscape?

Major companies operating in the superficial punctate keratitis treatment market are prioritizing innovative products, such as developing eye drops, to address underlying inflammation and offer patients effective, non-invasive treatment options. Eye drops are liquid solutions designed for direct application to the eyes, utilized to manage conditions like irritation, dryness, inflammation, or infections. For instance, in May 2023, Entod Pharmaceuticals, an India-based pharmaceutical firm, launched CYCLOTEARS eye drops in India and other global regions for individuals experiencing inflammatory dry eye disease (DED). This represents the world’s first dry eye therapy to feature the company’s self-emulsifying drug delivery system (SEDDS) technology, marking a significant advancement in treating eye inflammation. This advanced formulation improves drug absorption and effectiveness, consequently offering enhanced relief for patients.

Who Are The Prominent Players Across The Surface Plasmon Resonance Market?

Major companies operating in the surface plasmon resonance market are GE HealthCare Technologies Inc., Sartorius AG, Cytiva, Bio-Rad Laboratories Inc., Bruker Corporation, HORIBA Ltd., Quanterix Corporation, Jubilant Biosys Limited, Quantum Design Inc., Reichert Inc., NanoSPR Devices, Creative BioMart Inc., Biocompare, Carterra Inc., NICOYA AB, Biosensing Instrument Inc., Plexera LLC, Insplorion AB, BioNavis Ltd., Affinité Instruments, IBIS Technologies B.V.

Access The Complete Surface Plasmon Resonance Market Report:

https://www.thebusinessresearchcompany.com/report/surface-plasmon-resonance-global-market-report

What Is The Largest Regional Market In The Surface Plasmon Resonance Market?

North America was the largest region in the surface plasmon resonance market in 2025. The regions covered in the surface plasmon resonance market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Surface Plasmon Resonance Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=20655&type=smp

Browse Through More Reports Similar to the Global Surface Plasmon Resonance Market 2026, By The Business Research Company

Magnetic Resonance Imaging Systems Devices And Equipment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/magnetic-resonance-imaging-systems-devices-and-equipment-global-market-report

Magnetic Resonance Imaging Coils Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/magnetic-resonance-imaging-coils-global-market-report

Artificial Intelligence In Magnetic Resonance Imaging Mri Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-magnetic-resonance-imaging-mri-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Market Value Trend Is Expected For The Tumor Marker Testing Market From 2026 To 2030?

The tumor marker testing market size has demonstrated significant growth in recent years. It is projected to increase from $18.6 billion in 2025 to $20.12 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.2%. The expansion observed in the historic period is attributable to escalating cancer incidence rates, the wider adoption of laboratory diagnostics in oncology, the expansion of hospital-based cancer testing services, the availability of established biochemical markers, and the proliferation of diagnostic laboratory networks.

The tumor marker testing market size is projected to experience substantial expansion over the upcoming years. It is anticipated to grow to $27.23 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.9%. The projected growth can be attributed to a rising demand for early cancer detection, the increasing adoption of precision oncology approaches, an expansion of companion diagnostics, the growing use of biomarkers in therapy selection, and advancements in cancer biomarker research. Major trends expected in the forecast period include the increasing adoption of multiplex tumor marker panels, a rising use of blood-based cancer diagnostics, the growing integration of tumor markers in treatment monitoring, an expansion of early cancer screening programs, and an enhanced focus on personalized oncology care.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20668&type=smp

What Important Drivers Are Powering The Tumor Marker Testing Market Growth?

The growing occurrence of cancer is projected to stimulate the expansion of the tumor marker testing market in the coming years. Cancer is a condition marked by the unrestricted proliferation of atypical cells within the body. These cells possess the capability to infiltrate adjacent tissues and disseminate to various bodily regions via the circulatory and lymphatic systems. The rise in cancer incidents can be attributed to factors like an aging demographic, heightened exposure to environmental elements, evolving lifestyle choices, and advancements in screening and identification methods. Tumor marker testing serves the purpose of diagnosing, observing the effectiveness of treatment, and identifying the re-occurrence of different cancers through the measurement of distinct substances generated by malignant cells. For instance, in October 2025, as reported by the National Health Service, a Uk-based government agency, in 2023, there were 354,820 new cancer diagnoses, equating to 972 per day on average, which was 8,605 more than in 2022. Consequently, the rising prevalence of cancer is fueling the growth of the tumor marker testing market.

Which Segment Divisions Form The Structure Of The Tumor Marker Testing Market?

The tumor marker testing market covered in this report is segmented –

1) By Product: Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines

2) By Methods: Screening, Imaging, Theranostics, Other Methods

3) By Application: Hospitals, Commercial Or Private Laboratories, Physician Offices Or Group Practices, Cancer Clinics, Ambulatory Care Centers

Subsegments:

1) By Biochemical Markers: Alpha-fetoprotein (AFP), Prostate-Specific Antigen (PSA), Carcinoembryonic Antigen (CEA), Cancer Antigen 125 (CA 125), Cancer Antigen 19-9 (CA 19-9), Human Chorionic Gonadotropin (hCG)

2) By Oncogenes: HER2 Or neu, KRAS, BRAF, EGFR (Epidermal Growth Factor Receptor), c-MYC, p53

3) By Growth Factors: Vascular Endothelial Growth Factor (VEGF), Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor-beta (TGF-β), Fibroblast Growth Factor (FGF), Insulin-like Growth Factor (IGF)

4) By Hormones: Estrogen Receptors (ER), Progesterone Receptors (PR), Thyroglobulin, Calcitonin, Adrenocorticotropic Hormone (ACTH), Gastrin

5) By Colony Stimulating Factors: Granulocyte Colony-Stimulating Factor (G-CSF), Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Macrophage Colony-Stimulating Factor (M-CSF)

6) By Lymphokines: Interleukin-2 (IL-2), Interferon-gamma (IFN-γ), Tumor Necrosis Factor-alpha (TNF-α), Interleukin-6 (IL-6)

What Trends Are Shaping The Tumor Marker Testing Market Structure?

Prominent companies operating within the tubular external fixation system market are prioritizing the development of advanced solutions, such as stable external fixation systems, to improve patient outcomes and boost the efficiency of orthopedic treatments. A stable external fixation system is a medical apparatus that externally immobilizes and stabilizes fractures, ensuring accurate bone alignment throughout the healing phase. For example, in September 2023, Orthofix Medical Inc., a US-based spine and orthopedics company, introduced the Galaxy Fixation Gemini system, a new stable external fixation system specifically designed for addressing fractures resulting from trauma in both lower and upper limbs. This system is distinguished by its availability in multiple sterile procedure kit configurations, offering a rapid, ready-to-use solution for medical professionals. This innovative system incorporates sterile procedure kits that eliminate the requirement for tray sterilization, leading to considerable reductions in costs and operating room delays. The system thereby enhances operational efficiency and is well-suited for swift deployment in trauma environments, making it a valuable addition to Orthofix’s array of procedural solutions.

Which Firms Are Competing In The Tumor Marker Testing Market?

Major companies operating in the tumor marker testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche AG, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson and Company (BD), Quest Diagnostics Inc., Agilent Technologies Inc, Hologic Inc., Illumina Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Qiagen N.V., DiaSorin S.p.A., Myriad Genetics, Ortho Clinical Diagnostics PLC, Veracyte Inc., Biodesix Inc., Biocept Inc., Proteomedix AG, OncoCyte Corporation, Biocartis NV

Access The Complete Tumor Marker Testing Market Report:

https://www.thebusinessresearchcompany.com/report/tumor-marker-testing-global-market-report

Which Region Commands The Largest Share Of The Tumor Marker Testing Market?

North America was the largest region in the tumor marker testing market in 2025. The regions covered in the tumor marker testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Tumor Marker Testing Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=20668&type=smp

Browse Through More Reports Similar to the Global Tumor Marker Testing Market 2026, By The Business Research Company

Circulating Tumor Cells Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/circulating-tumor-cells-global-market-report

Tumor Necrosis Factor Inhibitor Drugs Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/tumor-necrosis-factor-inhibitor-drugs-global-market-report

Tumor Infiltrating Lymphocytes Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/tumor-infiltrating-lymphocytes-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Tumor Marker Testing Market Between 2026 And 2030?

The tumor marker testing market has shown considerable growth in recent years. This market is anticipated to expand from $18.6 billion in 2025 to $20.12 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.2%. The increase observed in the past can be ascribed to several factors, including the rising incidence of cancer, the more extensive application of laboratory diagnostics within oncology, the expansion of cancer testing services offered by hospitals, the presence of established biochemical markers, and the development of diagnostic laboratory networks.

The tumor marker testing market size is projected to experience substantial growth in the upcoming years. It is anticipated to reach $27.23 billion by 2030, at a compound annual growth rate (CAGR) of 7.9%. This growth throughout the forecast period can be attributed to an increasing demand for early cancer detection, the rising adoption of precision oncology methods, the expansion of companion diagnostics, the growing application of biomarkers in therapy selection, and ongoing advancements in cancer biomarker research. Major trends expected during the forecast period include the increasing adoption of multiplex tumor marker panels, the rising use of blood-based cancer diagnostics, the deeper integration of tumor markers in treatment monitoring, the wider expansion of early cancer screening programs, and an enhanced focus on personalized oncology care.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20668&type=smp

Which Key Drivers Are Affecting The Tumor Marker Testing Market Development?

The growing incidence of cancer is anticipated to propel the expansion of the tumor marker testing market in the future. Cancer is a condition characterized by the unrestrained proliferation of abnormal cells within the body. These cells have the capacity to invade adjacent tissues and spread to other bodily regions through the bloodstream and lymphatic systems. The escalation in cancer rates is influenced by factors such as aging populations, increased environmental exposures, changes in lifestyle, and enhancements in detection and diagnosis. Tumor marker testing is employed to diagnose, monitor treatment efficacy, and detect recurrence in various cancers by measuring specific substances produced by cancer cells. For instance, in October 2025, according to the National Health Service, a Uk-based government agency, in 2023, there were 354,820 new cancer diagnoses, or 972 per day on average, 8,605 higher than in 2022. Thus, the increasing cancer prevalence is fostering the growth of the tumor marker testing market.

What Segment Categories Shape The Tumor Marker Testing Market Segment Landscape?

The tumor marker testing market covered in this report is segmented –

1) By Product: Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines

2) By Methods: Screening, Imaging, Theranostics, Other Methods

3) By Application: Hospitals, Commercial Or Private Laboratories, Physician Offices Or Group Practices, Cancer Clinics, Ambulatory Care Centers

Subsegments:

1) By Biochemical Markers: Alpha-fetoprotein (AFP), Prostate-Specific Antigen (PSA), Carcinoembryonic Antigen (CEA), Cancer Antigen 125 (CA 125), Cancer Antigen 19-9 (CA 19-9), Human Chorionic Gonadotropin (hCG)

2) By Oncogenes: HER2 Or neu, KRAS, BRAF, EGFR (Epidermal Growth Factor Receptor), c-MYC, p53

3) By Growth Factors: Vascular Endothelial Growth Factor (VEGF), Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor-beta (TGF-ß), Fibroblast Growth Factor (FGF), Insulin-like Growth Factor (IGF)

4) By Hormones: Estrogen Receptors (ER), Progesterone Receptors (PR), Thyroglobulin, Calcitonin, Adrenocorticotropic Hormone (ACTH), Gastrin

5) By Colony Stimulating Factors: Granulocyte Colony-Stimulating Factor (G-CSF), Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Macrophage Colony-Stimulating Factor (M-CSF)

6) By Lymphokines: Interleukin-2 (IL-2), Interferon-gamma (IFN-?), Tumor Necrosis Factor-alpha (TNF-a), Interleukin-6 (IL-6)

What Trends Are Transforming The Tumor Marker Testing Market?

Entities engaged in the tumor marker testing market are increasingly prioritizing the development of advanced diagnostic tools, such as molecular testing solutions, to enhance their competitive standing. Molecular testing solutions refer to sophisticated diagnostic techniques that analyze genetic material (DNA or RNA) to identify mutations, pathogens, or specific biomarkers at a molecular level. As an illustration, in April 2024, RGCC International GmbH, a company based in Switzerland specializing in personalized cancer treatment, launched Onco-D-clare, a revolutionary cancer detection test. This innovative test empowers individuals to detect cancer prior to the onset of symptoms by combining molecular biology and artificial neural networks. Onco-D-clare operates by isolating peripheral blood mononuclear cells from blood samples, subsequently conducting a comprehensive analysis of gene expression across more than 90 genes.

Who Are The Companies Operating Across The Tumor Marker Testing Market Value Chain?

Major companies operating in the tumor marker testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche AG, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson and Company (BD), Quest Diagnostics Inc., Agilent Technologies Inc, Hologic Inc., Illumina Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Qiagen N.V., DiaSorin S.p.A., Myriad Genetics, Ortho Clinical Diagnostics PLC, Veracyte Inc., Biodesix Inc., Biocept Inc., Proteomedix AG, OncoCyte Corporation, Biocartis NV

Get The Full Tumor Marker Testing Market Report:

https://www.thebusinessresearchcompany.com/report/tumor-marker-testing-global-market-report

Which Region Represents The Largest Share Of The Tumor Marker Testing Market?

North America was the largest region in the tumor marker testing market in 2025. The regions covered in the tumor marker testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Tumor Marker Testing Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/tumor-marker-testing-global-market-report

Browse Through More Reports Similar to the Global Tumor Marker Testing Market 2026, By The Business Research Company

Circulating Tumor Cells Market Report 2026

https://www.thebusinessresearchcompany.com/report/circulating-tumor-cells-global-market-report

Tumor Necrosis Factor Inhibitor Drugs Market Report

https://www.thebusinessresearchcompany.com/report/tumor-necrosis-factor-inhibitor-drugs-global-market-report

Tumor Infiltrating Lymphocytes Market Report

https://www.thebusinessresearchcompany.com/report/tumor-infiltrating-lymphocytes-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Surface Plasmon Resonance Market Between 2026 And 2030?

The surface plasmon resonance market has experienced significant expansion over recent years. It is forecast to grow from $1.33 billion in 2025 to $1.49 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.8%. This historical growth can be linked to the broadening of pharmaceutical and biotech research activities, the increased utilization of biomolecular interaction studies, developments in academic life science research, the escalating demand for analytical precision tools, and the introduction of advanced optical sensing technologies.

The surface plasmon resonance market is projected to experience swift expansion over the coming years. This market is anticipated to reach a valuation of $2.3 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.5%. Factors driving this growth during the forecast timeframe include augmented investment in the development of biologics and biosimilars, a growing need for high-throughput screening instruments, the broadening scope of personalized medicine research, the expanding use of biosensors in diagnostic applications, and an intensified focus on real-time molecular analysis. Key trends observed within the forecast period encompass a greater uptake of high-sensitivity SPR imaging systems, an escalating requirement for label-free biomolecular analysis, the increasing incorporation of SPR into drug discovery workflows, the proliferation of portable and multi-channel SPR sensors, and a heightened emphasis on real-time interaction studies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20655&type=smp

What Leading Drivers Are Supporting The Surface Plasmon Resonance Market Expansion?

The increasing integration of personalized medicine is projected to accelerate the expansion of the surface plasmon resonance market moving forward. Personalized medicine represents a customized healthcare strategy that utilizes an individual’s genetic makeup, environmental influences, and lifestyle choices to formulate bespoke treatment and prevention plans. This growing uptake of personalized medicine is propelled by breakthroughs in genomics, the emergence of targeted therapies, and the increasing demand for more precise and effective interventions. Surface plasmon resonance contributes to personalized medicine by enabling the real-time examination of biomolecular interactions, assisting in the identification of specific biomarkers, and optimizing drug therapies specifically for individual patients. For instance, in February 2024, as reported by the Personalized Medicine Coalition, a US-based hospital and health care organization, the FDA gave its approval to 16 new personalized treatments for rare disease patients in 2023, which is an increase from 6 in 2022. The newly approved personalized treatments for 2023 additionally included seven cancer drugs and three for other diseases and conditions. Therefore, the expanding adoption of personalized medicine is a key driver for the growth of the surface plasmon resonance market.

How Is The Surface Plasmon Resonance Market Organized By Segment Classification?

The surface plasmon resonance market covered in this report is segmented –

1) By Product Type: Imaging System, Sensor System, Reagents

2) By Technology: Prism-Based Surface Plasmon Resonance (SPR), Grating-Based Surface Plasmon Resonance (SPR), Other Technologies

3) By Application: Drug Discovery, Drug Formulation, Controlled Drug Release, Drug Cell Interaction, Material Science, Biosensors

4) By End-User: Academic And Research Institutes, Food And Beverage Industry, Biopharmaceutical Companies, Contract Research Organizations (CROs), Other End-Users

Subsegments:

1) By Imaging System: 2D Imaging Systems, 3D Imaging Systems, High-Resolution Imaging Systems

2) By Sensor System: Optical Sensor Systems, Portable Sensor Systems, Multi-channel Sensor Systems

3) By Reagents: Binding Reagents, Sample Preparation Reagents, Stabilizing Reagents

What Emerging Trends Are Seen In The Surface Plasmon Resonance Market?

Leading companies active in the surface plasmon resonance market are concentrating on creating sophisticated biomolecular analysis technologies, including high-throughput SPR biosensor platforms, to achieve a competitive edge. SPR operates by utilizing an optical phenomenon at metal–dielectric interfaces to identify binding events in real time without labels. For instance, in February 2023, Carterra, a US-based biotechnology instrumentation company, introduced its high-throughput SPR platform, the LSA^XT, which provides improved sensitivity, substantially increased sample throughput, and minimized sample consumption, thereby enabling the efficient screening of membrane proteins, small molecules, and kinetic interactions. Such sensitive, high-throughput SPR systems empower pharmaceutical and biotech businesses to accelerate drug discovery and biologics characterization. However, this evolution also places greater demands on instrument vendors to ensure reproducibility and manage larger volumes of data.

Who Are The Industry Participants Involved In The Surface Plasmon Resonance Market?

Major companies operating in the surface plasmon resonance market are GE HealthCare Technologies Inc., Sartorius AG, Cytiva, Bio-Rad Laboratories Inc., Bruker Corporation, HORIBA Ltd., Quanterix Corporation, Jubilant Biosys Limited, Quantum Design Inc., Reichert Inc., NanoSPR Devices, Creative BioMart Inc., Biocompare, Carterra Inc., NICOYA AB, Biosensing Instrument Inc., Plexera LLC, Insplorion AB, BioNavis Ltd., Affinité Instruments, IBIS Technologies B.V.

Get The Full Surface Plasmon Resonance Market Report:

https://www.thebusinessresearchcompany.com/report/surface-plasmon-resonance-global-market-report

Where Is The Surface Plasmon Resonance Market Most Concentrated Geographically?

North America was the largest region in the surface plasmon resonance market in 2025. The regions covered in the surface plasmon resonance market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Surface Plasmon Resonance Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/surface-plasmon-resonance-global-market-report

Browse Through More Reports Similar to the Global Surface Plasmon Resonance Market 2026, By The Business Research Company

Magnetic Resonance Imaging Systems Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/magnetic-resonance-imaging-systems-devices-and-equipment-global-market-report

Magnetic Resonance Imaging Coils Market Report

https://www.thebusinessresearchcompany.com/report/magnetic-resonance-imaging-coils-global-market-report

Artificial Intelligence In Magnetic Resonance Imaging Mri Market Report

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-magnetic-resonance-imaging-mri-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Tumor Marker Testing Market Evolve From 2026 To 2030?

The tumor marker testing market has experienced robust expansion in recent years. This market is projected to expand from $18.6 billion in 2025 to $20.12 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.2%. Historically, this expansion has been driven by factors such as a rise in cancer incidence rates, the increased adoption of laboratory diagnostics within oncology, the broadening of hospital-based cancer testing services, the presence of well-established biochemical markers, and the development of diagnostic laboratory networks.

The tumor marker testing market is projected to experience substantial expansion over the upcoming years. This market is set to reach $27.23 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.9%. Factors driving this growth during the projected timeframe include the escalating need for prompt cancer identification, the wider implementation of precision oncology strategies, the broadening scope of companion diagnostics, the increasing application of biomarkers for selecting therapies, and progress in cancer biomarker investigations. Key trends anticipated within this forecast period encompass the greater uptake of multiplex tumor marker panels, the surge in the utilization of blood-based cancer diagnostics, the increasing incorporation of tumor markers into treatment oversight, the expansion of initiatives for early cancer screening, and a heightened emphasis on individualized oncology care.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20668&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Tumor Marker Testing Market?

The rising incidence of cancer is anticipated to fuel the expansion of the tumor marker testing market in the future. Cancer is defined as a condition marked by the uncontrolled multiplication of atypical cells within the body. These malignant cells possess the ability to infiltrate adjacent tissues and disseminate to various bodily regions via the bloodstream and lymphatic systems. The escalation in cancer rates stems from contributors like an aging populace, heightened exposure to environmental factors, shifts in lifestyle, and advancements in detection and diagnostic methods. Tumor marker testing serves the purpose of diagnosing, tracking the effectiveness of treatment, and identifying the re-emergence of different cancers through the measurement of particular substances generated by cancerous cells. As an illustration, the National Health Service, a Uk-based government agency, reported that in October 2025, the year 2023 saw 354,820 new cancer diagnoses, averaging 972 daily, which represented an increase of 8,605 compared to 2022. Consequently, the escalating prevalence of cancer is propelling the growth of the tumor marker testing market.

Which Segment Areas Are Covered In The Tumor Marker Testing Market Analysis?

The tumor marker testing market covered in this report is segmented –

1) By Product: Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines

2) By Methods: Screening, Imaging, Theranostics, Other Methods

3) By Application: Hospitals, Commercial Or Private Laboratories, Physician Offices Or Group Practices, Cancer Clinics, Ambulatory Care Centers

Subsegments:

1) By Biochemical Markers: Alpha-fetoprotein (AFP), Prostate-Specific Antigen (PSA), Carcinoembryonic Antigen (CEA), Cancer Antigen 125 (CA 125), Cancer Antigen 19-9 (CA 19-9), Human Chorionic Gonadotropin (hCG)

2) By Oncogenes: HER2 Or neu, KRAS, BRAF, EGFR (Epidermal Growth Factor Receptor), c-MYC, p53

3) By Growth Factors: Vascular Endothelial Growth Factor (VEGF), Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor-beta (TGF-ß), Fibroblast Growth Factor (FGF), Insulin-like Growth Factor (IGF)

4) By Hormones: Estrogen Receptors (ER), Progesterone Receptors (PR), Thyroglobulin, Calcitonin, Adrenocorticotropic Hormone (ACTH), Gastrin

5) By Colony Stimulating Factors: Granulocyte Colony-Stimulating Factor (G-CSF), Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Macrophage Colony-Stimulating Factor (M-CSF)

6) By Lymphokines: Interleukin-2 (IL-2), Interferon-gamma (IFN-?), Tumor Necrosis Factor-alpha (TNF-a), Interleukin-6 (IL-6)

Which Trends Are Shaping The Future Of The Tumor Marker Testing Market?

Leading companies engaged in the tumor marker testing market are intensifying their efforts to develop sophisticated tests, like molecular testing solutions, to achieve a competitive edge. Molecular testing solutions are defined as advanced diagnostic methods that examine genetic material (DNA or RNA) to identify mutations, pathogens, or particular biomarkers at a molecular level. For instance, in April 2024, RGCC International GmbH, a Switzerland-based firm specializing in personalized cancer treatment, launched Onco-D-clare, an innovative cancer detection test. This novel test empowers individuals to detect cancer before symptoms emerge by utilizing a combination of molecular biology and artificial neural networks. Onco-D-clare operates by extracting peripheral blood mononuclear cells from blood samples and then performing an extensive gene expression analysis across more than 90 genes.

Which Global Companies Are Actively Competing In The Tumor Marker Testing Market?

Major companies operating in the tumor marker testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche AG, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson and Company (BD), Quest Diagnostics Inc., Agilent Technologies Inc, Hologic Inc., Illumina Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Qiagen N.V., DiaSorin S.p.A., Myriad Genetics, Ortho Clinical Diagnostics PLC, Veracyte Inc., Biodesix Inc., Biocept Inc., Proteomedix AG, OncoCyte Corporation, Biocartis NV

Read the full tumor marker testing market report here:

https://www.thebusinessresearchcompany.com/report/tumor-marker-testing-global-market-report

What Are The Leading Geographic Regions In The Tumor Marker Testing Market?

North America was the largest region in the tumor marker testing market in 2025. The regions covered in the tumor marker testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Tumor Marker Testing Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20668&type=smp

Browse Through More Reports Similar to the Global Tumor Marker Testing Market 2026, By The Business Research Company

Circulating Tumor Cells Global Market Report

https://www.thebusinessresearchcompany.com/report/circulating-tumor-cells-global-market-report

Tumor Necrosis Factor Inhibitor Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/tumor-necrosis-factor-inhibitor-drugs-global-market-report

Tumor Infiltrating Lymphocytes Global Market Report

https://www.thebusinessresearchcompany.com/report/tumor-infiltrating-lymphocytes-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Surface Plasmon Resonance Market By 2030 Starting From Its 2026 Size?

The surface plasmon resonance market has experienced substantial expansion in recent years. It is projected to grow from $1.33 billion in 2025 to $1.49 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.8%. This historical growth can be attributed to the broadening of pharmaceutical and biotech research activities, a greater utilization of biomolecular interaction studies, the growth in academic life science research, an escalating demand for analytical precision tools, and the availability of advanced optical sensing technologies.

The surface plasmon resonance market size is anticipated to experience swift expansion in the coming years. It is projected to reach $2.3 billion by 2030, growing at a compound annual growth rate (CAGR) of 11.5%. This growth throughout the forecast period can be attributed to several factors, including increasing investment in the development of biologics and biosimilars, a rising demand for high-throughput screening tools, the expansion of personalized medicine research, growing adoption of biosensors in diagnostics, and a heightened focus on real-time molecular analytics. Furthermore, significant trends expected during this period involve the increasing adoption of high-sensitivity SPR imaging systems, a rising demand for label-free biomolecular analysis, the growing integration of SPR in drug discovery pipelines, the expansion of portable and multi-channel SPR sensors, and an enhanced focus on real-time interaction analysis.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20655&type=smp

What Primary Drivers Are Shaping The Development Of The Surface Plasmon Resonance Market?

The future expansion of the surface plasmon resonance market is anticipated to be fueled by the rising embrace of personalized medicine. This approach to healthcare involves customizing treatment and prevention plans based on an individual’s unique genetic makeup, environmental influences, and lifestyle choices. The growing acceptance of personalized medicine stems from progress in genomics, the emergence of targeted therapies, and a greater need for treatments that are both more exact and efficacious. Surface plasmon resonance plays a crucial role in personalized medicine by facilitating the real-time examination of biomolecular interactions, assisting in the identification of particular biomarkers, and fine-tuning drug regimens for individual patients. For example, in February 2024, the Personalized Medicine Coalition, a US-based hospital and health care organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, marking an increase from 6 in 2022. Among the personalized treatments approved in 2023 were also seven cancer drugs and three for other diseases and conditions. Consequently, the expanding use of personalized medicine is a key impetus for the surface plasmon resonance market’s development.

Which Segment Categories Define The Surface Plasmon Resonance Market?

The surface plasmon resonance market covered in this report is segmented –

1) By Product Type: Imaging System, Sensor System, Reagents

2) By Technology: Prism-Based Surface Plasmon Resonance (SPR), Grating-Based Surface Plasmon Resonance (SPR), Other Technologies

3) By Application: Drug Discovery, Drug Formulation, Controlled Drug Release, Drug Cell Interaction, Material Science, Biosensors

4) By End-User: Academic And Research Institutes, Food And Beverage Industry, Biopharmaceutical Companies, Contract Research Organizations (CROs), Other End-Users

Subsegments:

1) By Imaging System: 2D Imaging Systems, 3D Imaging Systems, High-Resolution Imaging Systems

2) By Sensor System: Optical Sensor Systems, Portable Sensor Systems, Multi-channel Sensor Systems

3) By Reagents: Binding Reagents, Sample Preparation Reagents, Stabilizing Reagents

What Key Developments And Trends Are Impacting The Surface Plasmon Resonance Market?

Leading firms within the surface plasmon resonance market are concentrating on creating sophisticated biomolecular analysis solutions, including high-throughput SPR biosensor platforms, to secure a competitive edge. SPR operates by utilizing an optical phenomenon occurring at metal–dielectric boundaries to identify real-time binding events without requiring labels. For example, in February 2023, Carterra, a US-based biotechnology instrumentation firm, introduced its high-throughput SPR platform, the LSA^XT. This platform provides enhanced sensitivity, substantially increased sample throughput, and decreased sample consumption, thus facilitating effective screening of membrane proteins, small molecules, and kinetic interactions. These highly sensitive, high-throughput SPR systems empower pharmaceutical and biotechnology companies to speed up drug discovery processes and biologics characterization. Nevertheless, this transition also puts more demands on instrument providers to guarantee reproducibility and handle expanded data volumes.

Who Are The Top Companies Competing In The Surface Plasmon Resonance Market?

Major companies operating in the surface plasmon resonance market are GE HealthCare Technologies Inc., Sartorius AG, Cytiva, Bio-Rad Laboratories Inc., Bruker Corporation, HORIBA Ltd., Quanterix Corporation, Jubilant Biosys Limited, Quantum Design Inc., Reichert Inc., NanoSPR Devices, Creative BioMart Inc., Biocompare, Carterra Inc., NICOYA AB, Biosensing Instrument Inc., Plexera LLC, Insplorion AB, BioNavis Ltd., Affinité Instruments, IBIS Technologies B.V.

Read the full surface plasmon resonance market report here:

https://www.thebusinessresearchcompany.com/report/surface-plasmon-resonance-global-market-report

How Does The Surface Plasmon Resonance Market Perform Across Major Global Regions?

North America was the largest region in the surface plasmon resonance market in 2025. The regions covered in the surface plasmon resonance market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Surface Plasmon Resonance Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20655&type=smp

Browse Through More Reports Similar to the Global Surface Plasmon Resonance Market 2026, By The Business Research Company

Magnetic Resonance Imaging Systems Devices And Equipment Global Market Report

https://www.thebusinessresearchcompany.com/report/magnetic-resonance-imaging-systems-devices-and-equipment-global-market-report

Magnetic Resonance Imaging Coils Global Market Report

https://www.thebusinessresearchcompany.com/report/magnetic-resonance-imaging-coils-global-market-report

Artificial Intelligence In Magnetic Resonance Imaging Mri Global Market Report

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-magnetic-resonance-imaging-mri-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Tumor Marker Testing Market Evolve From 2026 To 2030?

The tumor marker testing market has experienced robust expansion in recent years. This market is projected to expand from $18.6 billion in 2025 to $20.12 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.2%. Historically, this expansion has been driven by factors such as a rise in cancer incidence rates, the increased adoption of laboratory diagnostics within oncology, the broadening of hospital-based cancer testing services, the presence of well-established biochemical markers, and the development of diagnostic laboratory networks.

The tumor marker testing market is projected to experience substantial expansion over the upcoming years. This market is set to reach $27.23 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.9%. Factors driving this growth during the projected timeframe include the escalating need for prompt cancer identification, the wider implementation of precision oncology strategies, the broadening scope of companion diagnostics, the increasing application of biomarkers for selecting therapies, and progress in cancer biomarker investigations. Key trends anticipated within this forecast period encompass the greater uptake of multiplex tumor marker panels, the surge in the utilization of blood-based cancer diagnostics, the increasing incorporation of tumor markers into treatment oversight, the expansion of initiatives for early cancer screening, and a heightened emphasis on individualized oncology care.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20668&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Tumor Marker Testing Market?

The rising incidence of cancer is anticipated to fuel the expansion of the tumor marker testing market in the future. Cancer is defined as a condition marked by the uncontrolled multiplication of atypical cells within the body. These malignant cells possess the ability to infiltrate adjacent tissues and disseminate to various bodily regions via the bloodstream and lymphatic systems. The escalation in cancer rates stems from contributors like an aging populace, heightened exposure to environmental factors, shifts in lifestyle, and advancements in detection and diagnostic methods. Tumor marker testing serves the purpose of diagnosing, tracking the effectiveness of treatment, and identifying the re-emergence of different cancers through the measurement of particular substances generated by cancerous cells. As an illustration, the National Health Service, a Uk-based government agency, reported that in October 2025, the year 2023 saw 354,820 new cancer diagnoses, averaging 972 daily, which represented an increase of 8,605 compared to 2022. Consequently, the escalating prevalence of cancer is propelling the growth of the tumor marker testing market.

Which Segment Areas Are Covered In The Tumor Marker Testing Market Analysis?

The tumor marker testing market covered in this report is segmented –

1) By Product: Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines

2) By Methods: Screening, Imaging, Theranostics, Other Methods

3) By Application: Hospitals, Commercial Or Private Laboratories, Physician Offices Or Group Practices, Cancer Clinics, Ambulatory Care Centers

Subsegments:

1) By Biochemical Markers: Alpha-fetoprotein (AFP), Prostate-Specific Antigen (PSA), Carcinoembryonic Antigen (CEA), Cancer Antigen 125 (CA 125), Cancer Antigen 19-9 (CA 19-9), Human Chorionic Gonadotropin (hCG)

2) By Oncogenes: HER2 Or neu, KRAS, BRAF, EGFR (Epidermal Growth Factor Receptor), c-MYC, p53

3) By Growth Factors: Vascular Endothelial Growth Factor (VEGF), Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor-beta (TGF-ß), Fibroblast Growth Factor (FGF), Insulin-like Growth Factor (IGF)

4) By Hormones: Estrogen Receptors (ER), Progesterone Receptors (PR), Thyroglobulin, Calcitonin, Adrenocorticotropic Hormone (ACTH), Gastrin

5) By Colony Stimulating Factors: Granulocyte Colony-Stimulating Factor (G-CSF), Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Macrophage Colony-Stimulating Factor (M-CSF)

6) By Lymphokines: Interleukin-2 (IL-2), Interferon-gamma (IFN-?), Tumor Necrosis Factor-alpha (TNF-a), Interleukin-6 (IL-6)

Which Trends Are Shaping The Future Of The Tumor Marker Testing Market?

Leading companies engaged in the tumor marker testing market are intensifying their efforts to develop sophisticated tests, like molecular testing solutions, to achieve a competitive edge. Molecular testing solutions are defined as advanced diagnostic methods that examine genetic material (DNA or RNA) to identify mutations, pathogens, or particular biomarkers at a molecular level. For instance, in April 2024, RGCC International GmbH, a Switzerland-based firm specializing in personalized cancer treatment, launched Onco-D-clare, an innovative cancer detection test. This novel test empowers individuals to detect cancer before symptoms emerge by utilizing a combination of molecular biology and artificial neural networks. Onco-D-clare operates by extracting peripheral blood mononuclear cells from blood samples and then performing an extensive gene expression analysis across more than 90 genes.

Which Global Companies Are Actively Competing In The Tumor Marker Testing Market?

Major companies operating in the tumor marker testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche AG, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson and Company (BD), Quest Diagnostics Inc., Agilent Technologies Inc, Hologic Inc., Illumina Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Qiagen N.V., DiaSorin S.p.A., Myriad Genetics, Ortho Clinical Diagnostics PLC, Veracyte Inc., Biodesix Inc., Biocept Inc., Proteomedix AG, OncoCyte Corporation, Biocartis NV

Read the full tumor marker testing market report here:

https://www.thebusinessresearchcompany.com/report/tumor-marker-testing-global-market-report

What Are The Leading Geographic Regions In The Tumor Marker Testing Market?

North America was the largest region in the tumor marker testing market in 2025. The regions covered in the tumor marker testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Tumor Marker Testing Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20668&type=smp

Browse Through More Reports Similar to the Global Tumor Marker Testing Market 2026, By The Business Research Company

Circulating Tumor Cells Global Market Report

https://www.thebusinessresearchcompany.com/report/circulating-tumor-cells-global-market-report

Tumor Necrosis Factor Inhibitor Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/tumor-necrosis-factor-inhibitor-drugs-global-market-report

Tumor Infiltrating Lymphocytes Global Market Report

https://www.thebusinessresearchcompany.com/report/tumor-infiltrating-lymphocytes-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Tumor Marker Testing Market Evolve From 2026 To 2030?

The tumor marker testing market has experienced robust expansion in recent years. This market is projected to expand from $18.6 billion in 2025 to $20.12 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.2%. Historically, this expansion has been driven by factors such as a rise in cancer incidence rates, the increased adoption of laboratory diagnostics within oncology, the broadening of hospital-based cancer testing services, the presence of well-established biochemical markers, and the development of diagnostic laboratory networks.

The tumor marker testing market is projected to experience substantial expansion over the upcoming years. This market is set to reach $27.23 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.9%. Factors driving this growth during the projected timeframe include the escalating need for prompt cancer identification, the wider implementation of precision oncology strategies, the broadening scope of companion diagnostics, the increasing application of biomarkers for selecting therapies, and progress in cancer biomarker investigations. Key trends anticipated within this forecast period encompass the greater uptake of multiplex tumor marker panels, the surge in the utilization of blood-based cancer diagnostics, the increasing incorporation of tumor markers into treatment oversight, the expansion of initiatives for early cancer screening, and a heightened emphasis on individualized oncology care.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20668&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Tumor Marker Testing Market?

The rising incidence of cancer is anticipated to fuel the expansion of the tumor marker testing market in the future. Cancer is defined as a condition marked by the uncontrolled multiplication of atypical cells within the body. These malignant cells possess the ability to infiltrate adjacent tissues and disseminate to various bodily regions via the bloodstream and lymphatic systems. The escalation in cancer rates stems from contributors like an aging populace, heightened exposure to environmental factors, shifts in lifestyle, and advancements in detection and diagnostic methods. Tumor marker testing serves the purpose of diagnosing, tracking the effectiveness of treatment, and identifying the re-emergence of different cancers through the measurement of particular substances generated by cancerous cells. As an illustration, the National Health Service, a Uk-based government agency, reported that in October 2025, the year 2023 saw 354,820 new cancer diagnoses, averaging 972 daily, which represented an increase of 8,605 compared to 2022. Consequently, the escalating prevalence of cancer is propelling the growth of the tumor marker testing market.

Which Segment Areas Are Covered In The Tumor Marker Testing Market Analysis?

The tumor marker testing market covered in this report is segmented –

1) By Product: Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines

2) By Methods: Screening, Imaging, Theranostics, Other Methods

3) By Application: Hospitals, Commercial Or Private Laboratories, Physician Offices Or Group Practices, Cancer Clinics, Ambulatory Care Centers

Subsegments:

1) By Biochemical Markers: Alpha-fetoprotein (AFP), Prostate-Specific Antigen (PSA), Carcinoembryonic Antigen (CEA), Cancer Antigen 125 (CA 125), Cancer Antigen 19-9 (CA 19-9), Human Chorionic Gonadotropin (hCG)

2) By Oncogenes: HER2 Or neu, KRAS, BRAF, EGFR (Epidermal Growth Factor Receptor), c-MYC, p53

3) By Growth Factors: Vascular Endothelial Growth Factor (VEGF), Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor-beta (TGF-ß), Fibroblast Growth Factor (FGF), Insulin-like Growth Factor (IGF)

4) By Hormones: Estrogen Receptors (ER), Progesterone Receptors (PR), Thyroglobulin, Calcitonin, Adrenocorticotropic Hormone (ACTH), Gastrin

5) By Colony Stimulating Factors: Granulocyte Colony-Stimulating Factor (G-CSF), Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Macrophage Colony-Stimulating Factor (M-CSF)

6) By Lymphokines: Interleukin-2 (IL-2), Interferon-gamma (IFN-?), Tumor Necrosis Factor-alpha (TNF-a), Interleukin-6 (IL-6)

Which Trends Are Shaping The Future Of The Tumor Marker Testing Market?

Leading companies engaged in the tumor marker testing market are intensifying their efforts to develop sophisticated tests, like molecular testing solutions, to achieve a competitive edge. Molecular testing solutions are defined as advanced diagnostic methods that examine genetic material (DNA or RNA) to identify mutations, pathogens, or particular biomarkers at a molecular level. For instance, in April 2024, RGCC International GmbH, a Switzerland-based firm specializing in personalized cancer treatment, launched Onco-D-clare, an innovative cancer detection test. This novel test empowers individuals to detect cancer before symptoms emerge by utilizing a combination of molecular biology and artificial neural networks. Onco-D-clare operates by extracting peripheral blood mononuclear cells from blood samples and then performing an extensive gene expression analysis across more than 90 genes.

Which Global Companies Are Actively Competing In The Tumor Marker Testing Market?

Major companies operating in the tumor marker testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche AG, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson and Company (BD), Quest Diagnostics Inc., Agilent Technologies Inc, Hologic Inc., Illumina Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Qiagen N.V., DiaSorin S.p.A., Myriad Genetics, Ortho Clinical Diagnostics PLC, Veracyte Inc., Biodesix Inc., Biocept Inc., Proteomedix AG, OncoCyte Corporation, Biocartis NV

Read the full tumor marker testing market report here:

https://www.thebusinessresearchcompany.com/report/tumor-marker-testing-global-market-report

What Are The Leading Geographic Regions In The Tumor Marker Testing Market?

North America was the largest region in the tumor marker testing market in 2025. The regions covered in the tumor marker testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Tumor Marker Testing Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20668&type=smp

Browse Through More Reports Similar to the Global Tumor Marker Testing Market 2026, By The Business Research Company

Circulating Tumor Cells Global Market Report

https://www.thebusinessresearchcompany.com/report/circulating-tumor-cells-global-market-report

Tumor Necrosis Factor Inhibitor Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/tumor-necrosis-factor-inhibitor-drugs-global-market-report

Tumor Infiltrating Lymphocytes Global Market Report

https://www.thebusinessresearchcompany.com/report/tumor-infiltrating-lymphocytes-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model